Verve Therapeutics Inc. is a biotechnology company focused on developing transformative gene editing therapies to treat cardiovascular diseases. The company was founded in 2018 and is based in Cambridge, Massachusetts, USA.
Verve Therapeutics is pioneering the use of gene editing technology to address the underlying genetic causes of cardiovascular diseases, such as coronary artery disease and high cholesterol. Their goal is to develop targeted therapies that can permanently and safely edit genes associated with these conditions, potentially offering patients a one-time treatment that provides long-lasting benefits.
The company's approach centers on using CRISPR/Cas9 gene editing technology to directly edit specific genes linked to cardiovascular diseases. By precisely modifying these genes, Verve Therapeutics aims to reduce the risk of developing heart-related conditions and potentially prevent heart attacks.
Verve Therapeutics collaborates with leading scientists, researchers, and experts in the field of cardiovascular genetics to advance its innovative therapies. Their research and development efforts are driven by a mission to revolutionize the treatment of cardiovascular diseases and improve the lives of patients affected by these conditions. As the field of gene editing continues to progress, Verve Therapeutics seeks to be at the forefront of therapeutic advancements in cardiovascular medicine.